You are here

  • Home
  • Online First
  • Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn’s disease

Article info

Article menu
Download PDFPDF
Inflammatory bowel disease
Original research
Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn’s disease

Authors

  • Li Zuo Anhui Medical University, Hefei, Anhui, ChinaDepartment of Pathology, Harvard Medical School, Boston, Massachusetts, USALaboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Wei-Ting Kuo Department of Pathology, Harvard Medical School, Boston, Massachusetts, USALaboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USAGraduate Institute of Oral Biology, National Taiwan University, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Feng Cao Laboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USADepartment of Otorhinolaryngology Head and Neck Surgery, Second People's Hospital of Hefei, Hefei, Anhui, China PubMed articlesGoogle scholar articles
  • Sandra D Chanez-Paredes Department of Pathology, Harvard Medical School, Boston, Massachusetts, USALaboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Daniel Zeve Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USADepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Prabhath Mannam Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Léa Jean-François Laboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Anne Day Laboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • W Vallen Graham Department of Pathology, The University of Chicago, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Yan Y Sweat Department of Pathology, Harvard Medical School, Boston, Massachusetts, USALaboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Nitesh Shashikanth Department of Pathology, Harvard Medical School, Boston, Massachusetts, USALaboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • David T Breault Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USADepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jerrold R Turner Department of Pathology, Harvard Medical School, Boston, Massachusetts, USALaboratory of Mucosal Barrier Pathobiology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USADepartment of Pathology, The University of Chicago, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jerrold R Turner, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; JRTURNER{at}BWH.HARVARD.EDU; Dr Li Zuo, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; lzuo{at}bwh.harvard.edu
View Full Text

Citation

Zuo L, Kuo W, Cao F, et al
Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn’s disease
Gut Published Online First: 10 May 2022. doi: 10.1136/gutjnl-2021-326534

Publication history

  • Received November 11, 2021
  • Accepted April 11, 2022
  • First published May 10, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.